Q-linea: A targeted ASTar launch strategy - Redeye

Q-linea is in the early stage of its targeted European launch strategy. The strong point is that Q-linea has developed a product ready for clinical use with positive initial feedback. The main go-to-market challenge is that it could take a bit longer to introduce ASTar in Europe without an international partner. The European market will require supporting clinical studies, including positive peer-to-peer review, before accepting rapid AST as a larger part of the standard of care.

Länk till analysen i sin helhet: https://www.redeye.se/research/890730/q-linea-a-targeted-astar-launch-strategy?utm_source=finwire&utm_medium=RSS